


PATENT  
Docket No. 529452000122

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on September 17 2004.

  
Christine Donahue

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of:

David W. MORRIS et al.

Serial No.: 10/087,192

Filing Date: March 1, 2002

For: NOVEL COMPOSITIONS AND  
METHODS FOR CANCER

Examiner: Not Yet Assigned

Group Art Unit: 1642

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 AND § 1.98**

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

The documents listed on the attached Form PTO-1449 were cited in an International Search Report mailed on July 26, 2004 and directed to counterpart international applications.

This Supplemental Information Disclosure Statement is submitted:

- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for


any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 529452000122. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: September 16, 2004

Respectfully submitted,

By:   
Shantanu Basu  
Registration No. 43,318

Morrison & Foerster LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
Telephone: (650) 813-5995  
Facsimile: (650) 494-0792



ALTERNATIVE TO PTO/SB/08a/b (08-03)

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/087,192
				Filing Date	March 1, 2002
				First Named Inventor	David W. MORRIS
				Art Unit	1642 1643
Examiner Name	Not Yet Assigned A. M. Harris				
Sheet	1	of	1	Attorney Docket Number	529452000122

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
amh	1.	Database GeneCore Accession No. U78076, created on May 14, 1999, last visited on October 24, 2004. Lee et al. "Cloning of Mouse Sepiapterin Reductase Gene and Characterization of its promoter Region," Gene Sequence, <i>Biochim Biophys Acta</i> (1999). Vol 1445, No. 1 pages 165-171. MPSRCH Search Report 2004, 1 page.	
amh	2.	International Search Report mailed on November 10, 2004 for PCT patent application no. PCT/US02/41414 filed December 26, 2002, 8 pages.	

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	amharris	Date Considered	07/22/2007
-----------------------	----------	--------------------	------------

pa-941962



12-17-04

1642

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/087,192	
	Filing Date	March 1, 2002	
	First Named Inventor	David W. MORRIS	
	Art Unit	1642	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	6 + 2 Refs.	Attorney Docket Number	529452000122

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	1. Form PTO/SB/08a/b (1 page in duplicate)
<input checked="" type="checkbox"/> Information Disclosure Statement (3 pages)	<input type="checkbox"/> CD, Number of CD(s) _____	2. References (2)
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	3. Return Receipt Postcard
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<b>Remarks</b>	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	MORRISON & FOERSTER LLP (Customer No. 25226)		
Signature			
Printed name	Shantanu Basu		
Date	December 15, 2004	Reg. No.	43,318

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV335376461US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 15, 2004

Signature:

(Georgina Matos)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV335376461US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 15, 2004

Signature:

*Georgina Matos*  
(Georgina Matos)

**PATENT**  
Docket No. 529452000122  
Client Reference No. 23696.001



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
David W. MORRIS et al.

Serial No.: 10/087,192

Filing Date: March 1, 2002

For: NOVEL COMPOSITIONS AND  
METHODS FOR CANCER

Examiner: Not Yet Assigned

Group Art Unit: 1642

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of documents are submitted herewith. The Examiner is requested to make these documents of record.

Application No. 10/087,192

The documents listed on the attached Form PTO/SB/08a/b were cited in an International Search Report mailed on November 10, 2004 directed to a counterpart international or foreign application. A certification under 37 C.F.R. § 1.97(e)(1) follows:

I hereby certify that each item of information was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \_\_ is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_ is enclosed.

Application No. 10/087,192

☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 529452000122. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: December 15, 2004

Respectfully submitted,

By Shantanu Basu  
Shantanu Basu  
Registration No.: 43,318  
MORRISON & FOERSTER LLP  
755 Page Mill Road  
Palo Alto, California 94304  
(650) 813-5995



Form PTO-1449

Docket Number 529452000122

Application Number 10/087,192

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)


Applicant

David W. MORRIS and Eric K. ENGELHARD

Filing Date March 1, 2002

Group Art Unit 1642 1643

Mailing Date April 16, 2003



## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
Amr	1.	12/18/1979	4,179,337	Davis et al.			
	2.	11/17/1981	4,301,144	Iwashita et al.			
	3.	09/04/1984	4,469,863	Ts'o et al.			
	4.	01/29/1985	4,496,689	Mitra			
	5.	02/03/1987	4,640,835	Shimizu et al.			
	6.	06/02/1987	4,670,417	Iwasaki et al.			
	7.	12/13/1988	4,791,192	Nakagawa et al.			
	8.	03/28/1989	4,816,567	Cabilly et al.			
	9.	07/23/1991	5,034,506	Summerton et al.			
	10.	06/23/1992	5,124,246	Urdea et al.			
	11.	06/01/1993	5,216,141	Benner			
	12.	08/10/1993	5,235,033	Summerton et al.			
	13.	10/25/1994	5,359,100	Urdea et al.			
	14.	11/31/1995	5,386,023	Sanghvi et al.			
	15.	08/29/1995	5,445,934	Fodor et al.			
	16.	08/13/1996	5,545,730	Urdea et al.			
	17.	08/13/1996	5,545,806	Lonberg et al.			
	18.	08/13/1996	5,545,807	Surani et al.			
	19.	10/29/1996	5,569,825	Lonberg et al.			
	20.	11/05/1996	5,571,670	Urdea et al.			
	21.	12/03/1996	5,580,731	Chang et al.			
	22.	01/07/1997	5,591,584	Chang et al.			
	23.	01/14/1997	5,594,117	Urdea et al.			
	24.	01/14/1997	5,594,118	Urdea et al.			
	25.	01/28/1997	5,597,909	Urdea et al.			
	26.	02/11/1997	5,602,240	De Mesmaeker et al.			

RECEIVED  
APR 29 2003  
TECH CENTER 1600/2900

EXAMINER: Amr Morris

DATE CONSIDERED: 23 July 2007

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



1642

PTO/SB/21 (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

8 + 14  
references

Application Number

10/087,192

Filing Date

March 1, 2002

First Named Inventor

David W. MORRIS

Art Unit

1642

Examiner Name

Not Yet Assigned

Attorney Docket  
Number

529452000122

## ENCLOSURES (Check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☐ Amendment/Reply

☐ After Final

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☐ Express Abandonment Request

☒ Information Disclosure Statement (3  
pages)

☐ Certified Copy of Priority  
Document(s)

☐ Response to Missing Parts/  
Incomplete Application

☐ Response to Missing Parts  
under 37 CFR 1.52 or 1.53

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a  
Provisional Application

☐ Power of Attorney, Revocation  
Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s) \_\_\_\_\_

Remarks

☐ After Allowance Communication  
to Group

☐ Appeal Communication to Board of  
Appeals and Interferences

☐ Appeal Communication to Group  
(Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s) (please  
identify below):

1. Form PTO-1449 + copy (4  
pages)
2. Fourteen (14) references
3. Return postcard

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm  
or  
Individual name

MORRISON & FOERSTER LLP  
Shantanu Basu - 43,318

25226

Signature

*Shantanu Basu*

Date

October 28, 2003

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 10/28/03

Signature: Mae Pattison (Mae Pattison)

Form PTO-1449

Docket Number 529452000122

Application Number 10/087,192

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

David W. MORRIS and Eric K. ENGELHARD

Filing Date March 1, 2002

Group Art Unit 1642

Mailing Date April 16, 2003

27.	04/29/1997	5,624,802	Urdea et al.
28.	04/29/1997	5,625,126	Lonberg et al.
29.	05/27/1997	5,633,425	Lonberg et al.
30.	06/03/1997	5,635,352	Urdea et al.
31.	06/10/1997	5,637,684	Cook et al.
32.	07/01/1997	5,644,048	Yau
33.	08/26/1997	5,661,016	Lonberg et al.
34.	10/28/1997	5,681,697	Urdea et al.
35.	10/28/1997	5,681,702	Collins et al.
36.	12/23/1997	5,700,637	Southern
37.	11/28/2000	6,153,441	Appelbaum et al.

RECEIVED

APR 29 2003

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
amh	38.	09/11/1987	WO 87/05330 ✓	WIPO			
	39.	09/20/1990	WO 90/10448 ✓	WIPO			
	40.	04/18/1991	WO 91/04753 ✓	WIPO			
	41.	11/11/1993	WO 93/22443 ✓	WIPO			
	42.	09/21/1995	WO 95/25116 ✓	WIPO			
	43.	12/28/1995	WO 95/35505 ✓	WIPO			
	44.	07/31/1997	WO 97/27212 ✓	WIPO			
	45.	07/31/1997	WO 97/27213 ✓	WIPO			

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
amh	46.	Allen, J. D. and Berns, A. (1996). "Complementation Tagging of Cooperating Oncogenes in Knockout Mice," <i>Cancer Biology</i> 7:299-306.
	47.	Altschul, S. F. and Gish, W. (1996). "Local Alignment Statistics" In <i>Methods in Enzymology</i> Vol. 266, Academic Press, Inc., pp. 460-480.
	48.	Altschul, S. F. et al. (1990). "Basic Local Alignment Search Tool," <i>J. Mol. Biol.</i> 215:403-410.

EXAMINER:

amh

DATE CONSIDERED:

22 July 2007

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



PATENT  
Docket No. 529452000122

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on October 28, 2003.

*Mae Pattison*

Mae Pattison

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

David W. MORRIS and Eric K.  
ENGELHARD

Serial No.: 10/087,192

Filing Date: March 1, 2002

For: NOVEL COMPOSITIONS AND  
METHODS FOR CANCER

Examiner: Not Yet Assigned

Group Art Unit: 1642

SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 AND § 1.98

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

APR 28 2003

PATENT &amp; TRADEMARK OFFICE

Docket Number 529452000122

Application Number 10/087,192

Applicant

David W. MORRIS and Eric K. ENGELHARD

Filing Date March 1, 2002

Group Art Unit 1642 1643

Mailing Date April 16, 2003

49. Aplin, J. D. and Wriston, Jr., J. C. (1981). "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids," *CRC Crit. Rev. Biochem.* pp. 259-306.
50. Arenberg, D. A. et al. (2001). "The Murine CC Chemokine, 6C-Kine, Inhibits Tumor Growth and Angiogenesis in a Human Lung Cancer SCID Mouse Model," *Cancer Immunol. Immunother.* 49:587-592.
51. Ausubel, F. M. et al., eds. (1992). Short Protocols in Molecular Biology. Greene Publishing Associates and John Wiley & Sons, pp. iii-xviii (Table of Contents Only).
52. Bai, J. et al. (1999). "Sequence Comparison of JSRV with Endogenous Proviruses: Envelope Genotypes and a Novel ORF With Similarity to a G-Protein-Coupled Receptor," *Virology* 258:333-343.
53. Beaucage, S. L. and Iyer, R. P. (1993). "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives," *Tetrahedron* 49(10):1925-1963.
54. Boener, P. et al. (1991). "Production of Antigen-Specific Human Monoclonal Antibodies from in Vitro-Primed Human Splenocytes," *J. Immunol.* 147(1):86-95.
55. Bolli, M. et al. (1994). "α-Bicyclo-DNA: Synthesis, Characterization, and Pairing Properties of α-DNA-Analogues with Restricted Conformational Flexibility in the Sugar-Phosphate Backbone," Chapter 7 In Carbohydrate Modifications in Antisense Research. ACS Symposium Series 580, Shanghvi, Y. S and Cook, P. D, eds, American Chemical Society, Washington, pp. 100-117.
56. Brill, W. et al. (1989). "Synthesis of Oligodeoxynucleoside Phosphoridithioates via Thioamidites," *J. Am Chem soc.* 111:2321-2322.
57. Brower, V. (1998). "Naked DNA Vaccines Come of Age," *Nature Biotechnology* 16:1304-1305.
58. Carlsson, C. et al. (1996). "Screening for Genetic Mutations," *Nature* 380:207 (1 page total).
59. Cole, S.P.C., et al. (1985). "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," In Monoclonal Antibodies and Cancer Therapy, Reisfeld, R. A. and Sell, S., ed., Alan R. Liss, New York, p. 77-96 (Includes Table of Contents).
60. Creighton, T. E., ed. (1983). "Posttranslational Covalent Modifications of Polypeptide Chains," Chapter 2.4 In Proteins: Structure and Molecular Properties. W. H. Freeman & Co., San Francisco pp. 78-86 (Includes Table of Contents).
61. David, G. S. and Reisfeld, R. A. (1974). "Protein Iodination with Solid State Lactoperoxidase," *Biochemistry* 13(5):1014-1021.
62. De Mesmaeker, A. et al. (1994). "Comparison of Rigid and Flexible Backbones in Antisense Oligonucleotides," *Bioorganic & Medicinal Chem. Lett.* 4(3):395-398.
63. De Mesmaeker, A. et al. (1994). "Novel Backbone Replacements for Oligonucleotides," Chapter 2 In Carbohydrate Modifications in Antisense Research, ACS Symposium Series 580.. Shanghvi, Y. S and Cook, P. D, eds, American Chemical Society, Washington, pp. 24-39.
64. Dempcy, R. O. et al. (1995). "Synthesis of a Thymidyl Pentamer of Deoxyribonucleic Guanidine and Binding Studies with DNA Homopolynucleotides," *Proc. Natl Acad. Sci. USA* 92:6097-6101.

EXAMINER:

Am Harris

DATE CONSIDERED:

23 July 2002

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

This Supplemental Information Disclosure Statement is submitted:

- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to

Form PTO-1449

Docket Number 529452000122

Application Number 10/087,192

Applicant

David W. MORRIS and Eric K. ENGELHARD

Filing Date March 1, 2002

Group Art Unit 1642 1643

Mailing Date April 16, 2003

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

65. Desbois, C. et al. (1996). "Exclusion of *Int-6* from PML Nuclear Bodies by Binding to the HTLV-1 Tax Oncoprotein," *Science* 273:951-953.
66. Devereux et al. (1984). "A Comprehensive Set of Sequence Analysis Programs for the VAX," *Nuc. Acid. Res.* 12(1):387-395.
67. Doudney, K. et al. (2001). "Comparative Physical and Transcript Maps of ~ 1 Mb around *looptail*, a Gene for Severe Neural Tube Defects on Distal Mouse Chromosome 1 and Human Chromosome 1q22-q23," *Genomics* 72(2):180-192.
68. Eckstein, F., ed. (1991). Oligonucleotides and Analogues: A Practical Approach, Oxford University Press, vii-xvii. (Table of Contents Only).
69. Edge, A. S. B. et al. (1981). "Deglycosylation of Glycoproteins by Trifluoromethanesulfonic Acid," *Anal. Biochem.* 118:131-137.
70. Egholm, M. (1993). "PNA Hybridizes to Complementary Oligonucleotides Obeying the Watson-Crick Hydrogenbonding," *Nature* 365:566-568.
71. Elgholm, M. et al. (1992). "Peptide Nucleic Acids (PNA). Oligonucleotide Analogues with an Achiral Peptide Backbone," *J. Am. Chem. Soc.* 114:1895-1897.
72. Erny, K. M. et al. (1996). "Involvement of the *Tpl-2/cot* Oncogene in MMTV Tumorigenesis," *Oncogene* 13:2015-2020.
73. Evan, G. I. et al. (1985). "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product," *Biology* 5(12):3610-3616.
74. Fan, L. et al. (2000). "Cutting Edge: Ectopic Expression of the Chemokine TCA4/SLC is Sufficient to Trigger Lymphoid Neogenesis," *J. Immunol.* 164(8):3955-3959.
75. Feng, D. F. & Doolittle, R. F. (1987). "Progressive Sequence Alignment as a Prerequisite to Correct Phylogenetic Trees," *J. Mol. Evol.* 25:351-360.
76. Field, J. et al. (1988). "Purification of a RAS-Responsive Adenylyl Cyclase Complex from *Saccharomyces Cerevisiae* by Use of a Epitope Addition Method," *Mol. Cell. Biol.* 8(5):2159-2165.
77. Fishwild, D. M. et al. (1996). "High-Avidity Human IgGk Monoclonal Antibodies from a Novel Strain of Minilocus Transgenic Mice," *Nature Biotechnology* 14:845-851.
78. Gallahan, D. and Callahan, R. (1987). "Mammary Tumorigenesis in Feral Mice: Identification of a New *int* Locus in Mouse Mammary Tumor Virus (Czech II)-Induced Mammary Tumors," *J. Virol.* 61(1):66-74.
79. Gao, X. and Jeffs, W. P. (1994). "Unusual Conformation of a 3'-thioformacetal Linkage in a DNA Duplex," *J. Biomolecular NMR* 4:17-34.
80. Germer, S. et al. (2000). "High-Throughput SNP Allele-Frequency Determination in Pooled DNA Samples by Kinetic PCR," *Genome Res.* 10:258-266.
81. Goding, J. W. (1986). "Production of Monoclonal Antibodies," Chapter 3 *In Monoclonal Antibodies: Principles and Practice*, Academic Press, Inc., 2<sup>nd</sup> edition, pp. 59-103.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 529452000122. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: October 28, 2003

Respectfully submitted,

By: Shantanu Basu

Shantanu Basu  
Registration No. 43,318

Morrison & Foerster LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
Telephone: (650) 813-5995  
Facsimile: (650) 494-0792



Form PTO-1449

Docket Number 529452000122

Application Number 10/087,192

Applicant

David W. MORRIS and Eric K. ENGELHARD

Filing Date March 1, 2002

Group Art Unit 1642 1643

Mailing Date April 16, 2003

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

82.	Hansen, G. M. et al. (2000). "Genetic Profile of Insertion Mutations in Mouse Leukemias and Lymphomas," <i>Genome Res.</i> 10(2):237-243.
83.	Heid, C. A et al. (1996). "Real Time Quantitative PCR," <i>Genome Research</i> 6:986-994.
84.	Herdewjn, P. et al. (1994). "Hexopyranosyl-Like Oligonucleotides," Chapter 6 In <u>Carbohydrate Modifications in Antisense Research</u> . Shanghvi, Y. S and Cook, P. D, eds, ACS Symposium Series 580, American Chemical Society, Washington, pp. 80-99.
85.	Higgins, D. G. and Sharp, P. M. (1989). "Fast and Sensitive Multiple Sequence Alignments on a Microcomputer," <i>CABIOS Communications</i> 5(2):151-153.
86.	Hoogenboom, H. R. and Winter, G. (1991). "By-Passing Immunisation Human Antibodies from Synthetic Repertoires of Germline V <sub>H</sub> Gene Segments Rearranged in Vitro," <i>J. Mol. Biol.</i> 227:381-388.
87.	Hopp, T. P. et al. (1988). "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification," <i>Biotechnology</i> 6:1204-1210.
88.	Horn, T. et al. (1996). "Oligonucleotides with Alternating Anionic and Cationic Phosphoramidate Linkages: Synthesis and Hybridization of Stereo-Uniform Isomers," <i>Tetrahedron Letters</i> 37(6):743-746.
89.	Hwang, H. C. et al. (2002). "Identification of Oncogenes Collaborating with p27 <sup>Kip1</sup> Loss by Insertional Mutagenesis and High-Throughput Insertion Site Analysis," <i>Proc. Natl Acad. Sci. USA</i> 99(17):11293-11298 (Includes supporting information).
90.	Jenkins, G. N. and Turner, N. J. (1995). "The Biosynthesis of Carbocyclic Nucleosides," <i>Chem. Soc. Rev.</i> pp. 169-176.
91.	Jones, P. T. et al. (1986). "Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse," <i>Nature</i> 321:522-525.
92.	Jonkers, J. and Berns, A. (1996). "Retroviral Insertional Mutagenesis as a Strategy to Identify Cancer Genes," <i>Biochim. Biophys. Acta</i> 1287:29-57.
93.	Joosten, M. et al. (2000). "Phenotyping of Evi 1, Evi 11/Cb2, and Evi 12 Transformed Leukemias Isolated from a Novel Panel of Cas-Br-M Murine Leukemia Virus-Infected Mice," <i>J. Virology</i> 268:308-318.
94.	Jung, M. P. et al. (1994). "Hybridization of alternating Cationic/Anionic Oligonucleotides to RNA Segments," <i>Nucleosides &amp; Nucleotides</i> 13(6&7):1597-1605.
95.	Karlin, S. and Altschul, S.F. (1993). "Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences," <i>Proc. Natl Acad. Sci. USA</i> 90:5873-5877.
96.	Köhler, G. and Milstein, C. (1975). "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> 256:495-497.
97.	Kohno, T. et al. (2000). "Identification of Genes Associated with the Progression of Adult T-Cell Leukemia (ATL)," <i>Jpn. J. Cancer Res.</i> 91:1103-1110.

EXAMINER:

Am Harris

DATE CONSIDERED:

23 July 2007

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 529452000122

Application Number 10/087,192

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Applicant


David W. MORRIS and Eric K. ENGELHARD

Filing Date March 1, 2002

Group Art Unit 1642

1043

Mailing Date April 16, 2003



- Lee, F. S. et al. (1995). "Insertional Mutagenesis Identifies a Member of the *Wnt* Gene Family as a Candidate Oncogene in the Mammary Epithelium of *int-2/Fgf-3* Transgenic Mice," *Proc. Natl. Acad. Sci. USA* 92:2268-2272.
99. Lee, S. Wong et al. (1999). "Cloning of Mouse Sepiapterin Reductase Gene and Characterization of its Promoter Region," *Biochimica and Biophysica Acta* 1445(1):165-171.
100. Letsinger, R. L. et al. (1986). "Effects of Pendant Groups at Phosphorus on Binding Properties of d-ApA Analogues," *Nucl. Acids. Res* 14(8):3487-3499.
101. Letsinger, R. L. et al. (1988). "Cationic Oligonucleotides," *J. Am. Chem. Soc.* 110:4470-4471.
102. Letsinger, R.L. and Mungall, W. S. (1970). "Phosphoramidate Analogs of Oligonucleotides," *J. Org. Chem* 35(11):3800-3803.
103. Li, J. et al. (1999). "Leukaemia Disease Genes: Large-Scale Cloning and Pathway Predictions," *Nature Genetics* 23:348-353.
104. Lockhart, D. J. et al. (1996). "Expression Monitoring by Hybridization High-Density Oligonucleotide Arrays," *Nature Biotechnology*, 14:1675-1680.
105. Lonberg, N. and Huszar, D. (1995). "Human Antibodies from Transgenic Mice," *Intern. Rev. Immunol.* 13:65-93.
106. Longberg, N. et al. (1994). "Antigen-Specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications," *Nature* 368:856-859.
107. Lund, A. H. et al. (2002). "Genome-Wide Retroviral Insertional Tagging of Genes Involved in Cancer in *Cdkn2a*-Deficient Mice," *Nature Genetics Advance online Publication* pp. 1-6.
108. Lutz-Freyermuth, C. et al. (1990). "Quantitative Determination That One of Two Potential RNA-Binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-Loop II of U1 RNA," *Proc. Natl Acad. Sci. USA* 87:6393-6397.
109. MacArthur, C. A. et al. (1995). "*Fgf-8*, Activated by Proviral Insertion, Cooperates with the *Wnt-1* Transgene in Murine Mammary Tumorigenesis," *J. Virol.* 69(4):2501-2507.
110. Maddry, J. A. et al. (1994). "Synthesis of Nonionic Olgonucleotide Analogues," Chapter 3 In *Carbohydrate Modifications in Antisense Research*. Shanghvi, Y. S and Cook, P. D, eds, ACS Symposium Series 580 American Chemical Society, Washington, pp. 40-51.
111. Mag, M. et al. (1991). "Synthesis and Selective Cleavage of an Oligodeoyncucleotide Containing a Bridged Internucleotide 5'-Phosphorotiate Linkage," *Nucleic Acids Res.* 19(7):1437-1441.
112. Marchetti, A. et al. (1995). "*Int-6*, a Highly Conserved, Widely Expressed Gene, is Mutated by Mouse Mammary Tumor Virus in Mammary Preneoplasia," *J. Virol.* 69(3):1932-1938.
113. Marks, J. D. et al. (1991). "By-Passing Immunization, Human Antibodies from V-Gene Libraries Displayed on Phage," *J. Mol. Biol.* 222:581-597.
114. Marks, J. D. et al. (1992). "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," *Bio/Technology* 10:779-783.

EXAMINER:

C. J. F. J. J.

DATE CONSIDERED:

12 July 2007

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Pocket Number 529452000122

Application Number 10/087,192

Applicant

David W. MORRIS and Eric K. ENGELHARD

Filing Date March 1, 2002

Group Art Unit 1642

Mailing Date April 16, 2003

115. Martin, G. A. et al. (1992). "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K<sup>+</sup> Channel Currents," *Science* 255:192-194.
116. Meier, C. et al. (1992). "Peptide Nucleic Acids (PNAs) -- Unusual Properties of Nonionic Oligonucleotide Analogues," *Angew Chem. Int. Ed. Engl.* 31(8):1008-1010.
117. Mikkers, H. et al. (2002). "High-Throughput Retroviral Tagging to Identify Components of Specific Signaling Pathways in Cancer," *Nature Genetics Advance Online Publication*, pp. 1-7.
118. Moore, A. S. (2001). "The Role of Chemoattraction in Cancer Metastases," *BioEssays* 23(8):674-676.
119. Morris, D. W. et al. (1986). "Transfer, by Selective Breeding, of the Pathogenic *Mtv-2* Endogenous Provirus from the GR strain to a Wild Mouse Line Free of Endogenous and Exogenous Mouse Mammary Tumor Virus," *J. Virol.* 58(2):247-252.
120. Morris, D. W. et al. (1990). "Insertion Mutation of the *Int-1* and *Int-2* Loci by Mouse Mammary Tumor Virus in Premalignant and Malignant Neoplasms from the GR Mouse Strain," *J. Virol.* 64(4):1794-1802.
121. Morrison, S. L. (1994). "Success in Specification," *Nature* 368:812-813.
122. Müller, A. et al. (2001). "Involvement of Chemokine Receptors in Breast Cancer Metastasis," *Nature* 410:50-56.
123. Needleman, S. B. and Wunsch, C. D. (1970). "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins," *J. Mol. Biol.* 48:443-453.
124. Neuberger, M. (1996). "Generating High-Avidity Human Mabs in Mice," *Nature Biotechnology* 14:826 (1 page total).
125. Nusse, R. and Varmus, H. E. (1982). "Many Tumors Induced by the Mouse Mammary Tumor Virus Contain a Provirus Integrated in the Same Region of the Host Genome," *Cell* 31:99-109.
126. Nygren, H. (1982). "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents," *J. Histochem. and Cytochem.* 30(5):407-412.
127. Paborsky, L. R. et al. (1990). "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen," *Protein Engineering* 3(6):547-553.
128. Pain, D. and Surolia, A. (1981). "Preparation of Protein A-Peroxidase Monoconjugate Using A Heterobifunctional Reagent, and its Use in Enzyme Immunoassays," *J. Immunol. Meth.* 40:219-230.
129. Palmarini, M. et al. (1999). "Jaagsiekte Sheep Retrovirus is Necessary and Sufficient to Induce a Contagious Lung Cancer in Sheep," *J. Virol.* 73(8):6964-6972.
130. Pauwels, R. et al. (1986). "Biological Activity of New 2-5A Analogues," *Chemica Scripta* 26:141-145.
131. Pearson, W. R. and Lipman, D. J. (1988). "Improved Tools for Biological Sequence Comparison," 85:2444-2448.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 529452000122

Application Number 10/087,192

INFORMATION DISCLOSURE CITATIONS  
IN AN APPLICATION

(Use several sheets if necessary)

David W. MORRIS and Eric K. ENGELHARD

Filing Date March 1, 2002

Group Art Unit 1642 1643

Mailing Date April 16, 2003

- Peters, G. et al. (1983). "Tumorigenesis by Mouse Mammary Tumor Virus: Evidence for a Common Region for Provirus Integration in Mammary Tumors," *Cell* 33:369-377.
133. Peters, G. et al. (1989). "The Mouse Homolog of the *Hst/k-FGF* Gene is Adjacent to *int-2* and is Activated by Proviral Insertion in Some Virally Induced Mammary Tumors," *Proc. Natl. Acad. Sci. USA* 86:5678-5682.
134. Pierce (1994). "Cross-Linking," *Pierce Catalog and Handbook* pp. 155-200.
135. Presta, L. G. (1992). "Antibody Engineering," *Current Opinion in Structural Biology* 2:593-596.
136. Rawls, R. L. (1997). "Optimistic About Antisense," *C & E News* pp. 35-40.
137. Riechmann, L. et al. (1988). "Reshaping Human Antibodies for Therapy," *Nature* 332:323-327.
138. Roelink, H. et al. (1990). "*Wnt-3*, a Gene Activated by Proviral Insertion in Mouse Mammary Tumors is Homologous to *int-1/Wnt-1* and is Normally Expressed in Mouse Embryos and Adult Brain," *Proc. Natl. Acad. Sci. USA* 87:4519-4523.
139. Sambrook, J. et al., eds. (1989). Molecular Cloning, a Laboratory Manual, Second Edition. Cold Spring Harbor Laboratory Press. pp.xi-xxxviii. (Table of Contents Only).
140. Scopes, R. K., ed. (1982). Protein Purification: Principles and Practice. Springer-Verlag, New York, Heidelberg, Berlin, pp. xi-xiii.
141. Shiramizu, B. et al. (1994). "Identification of a Common Clonal Human Immunodeficiency Virus Integration Site in Human Immunodeficiency Virus-Associated Lymphomas," *Cancer Res.* 54:2069-2072.
142. Smith, T. F. and Waterman, M. S. (1981). "Comparison of Biosequences," *Adv. Appl. Math.* 2:482-489.
143. Sojar, H. T. and Bahl, O. P. (1987). "A Chemical Method for the Deglycosylation of Proteins," *Archives of Biochemistry and Biophysics* 259(1):52-57.
144. Sorensen, A. B. et al. (1993). "Amplification and Sequence Analysis of DNA Flanking Integrated Proviruses by a Simple Two-Step Polymerase Chain Reaction Method," *Journal of Virology* 67(12):7118-7124.
145. Sorensen, A. B. et al. (1993). "Sequence Tags for Provirus Integration Sites in DNAs of Tumors Induced by the Murine Retrovirus SL3-3," *Journal of Virology* 70(6):4063-4070.
146. Sorensen, A. B. et al. (2000). "Sintl, a Common Integration Site in SL3-3-Induced T-Cell Lymphomas, Harbors a Putative Proto-Oncogene with Homology to the Septin Gene Family," *J. Virology* 74(5):2161-2168.
147. Sprinzl, M. et al. (1977). "Enzymatic Incorporation of ATP and CTP Analogues Into the 3' End of tRNA," *Eur. J. Biochem* 81:579-589.
148. Stein, C. A. and Cohen, J. S. (1988). "Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review," *Cancer Res.* 48:2659-2668.
149. Sternsdorf, T. et al. (1997). "Nuclear Dots: Actors on Many Stages," *Immunobiology* 198:307-331.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 529452000122

Application Number 10/087,192

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Applicant


David W. MORRIS and Eric K. ENGELHARD

Filing Date March 1, 2002

Group Art Unit 1642

1643

Mailing Date April 16, 2003



- |      |   |
|------|---|
|      | Suzuki, T. et al. (2002). "New Genes Involved in Cancer Identified by Retroviral Tagging," <i>Nature Genetics Advance Online Publication</i> pp. 1-9.   |
| 151. | Suzuki, T. et al. (2002). "Web Note A: CIS Definition, Retroviral Tagging in the Post-Genome Era Identifies New Genes Involved in Cancer". (1 page total).  |
| 152. | Thotakura, N. R. and Bahl, O. P. (1987). "Enzymatic Deglycosylation of Glycoproteins," <i>In Methods in Enzymology</i> Academic Press, Inc., Vol. 138. pp. 350-359.   |
| 153. | Tijssen (1993). "Overview of Principles of Hybridization and the strategy of nucleic acid assays," Chapter 2 <i>In Laboratory Techniques in Biochemistry and Molecular Biology</i> , Hybridization with Nucleic Acid Probes, Van der Vliet, P. C., ed. Elsevier, Amsterdam, London, New York, and Tokyo, Volume 24 pp. 20-78. |
| 154. | Van der Krol, A. R et al. (1988). "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences," <i>Biotechniques</i> 6(10):958-976.   |
| 155. | Varmus, H. E. (1983). "Using Retroviruses as Insertional Mutagens to Identify Cellular Oncogenes," <i>In Oncogenes and Retroviruses: Evaluation of Basic Findings and Clinical Potential</i> . Alan R. Liss, Inc., New York. pp. 23-35.   |
| 156. | Vaughn, J. et al. (2000). "Genomic Structure and Expression of Human <i>KCNJ9</i> (Kir3.3/GIRK3)," <i>Biochem. Biophys. Res. Commun.</i> 274(2):302-309.  |
| 157. | Verhoeyen, M. et al. (1988). "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <i>Science</i> 239:1534-1536.   |
| 158. | von Kiedrowski, G. et al. (1991). "Parabolic Growth of a Self-Replicating Hexadeoxynucleotide Bearing a 3'-5'-Phosphoamidate Linkage," <i>Angew. Chem. Int. Ed. Engl</i> 30(4):423-426.   |
| 159. | Washington University. (2002). "Washington University BLAST Archives" located at <a href="http://blast.wustl">http://blast.wustl</a> visited on December 15, 2002.  |
| 160. | Wolford, J. K. (2001). "Analysis of Linkage Disequilibrium Between Polymorphisms in the <i>KCNJ9</i> Gene with Type 2 Diabetes Mellitus in Pima Indians," <i>Mol. Genet. Metab</i> 73(1):97-103.  |
| 161. | Zhang, W-X and Yang, S. Y. (2000). "Cloning and Characterization of a New Member of the T-Box Gene Family," <i>Genomics</i> 70(1):41-48.  |
| 162. | Zlokarnik, G. et al. (1998). "Quantitation of Transcription and Clonal Selection of Single Living Cells with $\beta$ -Lactamase as Reporter," <i>Science</i> 279:84-88.   |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 529452000122

Application Number 10/087,192

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Applicant

David W. MORRIS et al.

Filing Date March 1, 2002

Group Art Unit 1642 1643

Mailing Date December 23, 2003

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
amb	1.	12/13/2001	WO 01/94629	WIPO			

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
amb	2.	International Search Report mailed on December 1, 2003, for PCT patent application no. PCT/US02/33835 filed on October 22, 2002, 4 pages.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 529452000122

Application Number 10/087,192

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

Applicant

David W. MORRIS and Eric K. ENGELHARD

Filing Date March 1, 2002

Group Art Unit 1642

1643

Mailing Date October 28, 2003

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
amr	1.	01/30/2003	WO 03/008583	WIPO			

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
NO REF. SUPPLIED	2.	Berns, A. (Date unknown). "Table A: Retroviral Insertion Sites in EμMyc and EμMyc; Pim1 <sup>+</sup> Pim2 <sup>+</sup> Lymphomas", published in the advance online issue of <i>Nature Genetics</i> , 13 pages total.
1	3.	Berns, A. (Date unknown). "Web Fig A," describing PIM protein actions, published in the advance online issue of the <i>Nature Genetics</i> , 1 page total.
	4.	Campbell, A. M. (1984). "The Production and Characterization of Rodent and Human Hybridomas," Chapter 1 In <i>Monoclonal Antibody Technology</i> . Burdon, R. H and van Knippenberg, P. H., eds, Elsevier, pp.1-32.
	5.	Database GenCore on STN, Accession NO. U52152, Schoots et al. "Cloning of Four Inwardly Rectifying Potassium Channels from Human," Direction Submission March 25, 1996 Amino Acid and Nucleic acid Sequences
	6.	Database GenCore on STN, on Accession Number AF275818, Yang et al. 23 July 2000. "A Family of Novel PR- Domain (PRDM) Genes as Candidate Tumor Suppressors"
	7.	Hunter, W. M. and Greenwood, F. C. (1962). "Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity," <i>Nature</i> 194:495-496.
	8.	Jiang, G-L et al. (2000). "The Yin-Yang of PR-Domain Family Genes in Tumorigenesis," <i>Histol. Histopathol.</i> 15(1):109-117.
V	9.	Lohuizen, V. (Date unknown). "Web Table A," describing genomic positions insertion site sequences analyzed against the Celera Mouse Genome Database (CMGD Release 12), published in the advance online issue of <i>Nature Genetics</i> , 9 pages total.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



**EXAMINER:** Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.